Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07147309Not Yet Recruiting

Multimodal PET Imaging With 18F-FDG/SV2A/TSPO for Resection Planning in Drug-Resistant Epilepsy

Role: lead

NCT06701734Not Yet Recruiting

Targeted Translocator Protein PET Imaging Evaluate Neuroinflammation of the Chronic Pain Patients

Role: lead

NCT04171882Unknown

Microglial Cells Activation Imaging Using PET-CT With 18F-DPA714

Role: lead

All 3 trials loaded